Regenxbio Says RGX-111, RGX-121 Placed on Clinical Hold by FDA; Shares Tumble Pre-Bell

MT Newswires Live01-28

Regenxbio (RGNX) said Wednesday that the US Food and Drug Administration has placed a clinical hold on its investigational gene therapies RGX-111 and RGX-121 for potential treatment of Hurler syndrome and Hunter syndrome, respectively.

The company said the FDA's decision regarding RGX-111 was made after a preliminary analysis of a case of neoplasm in an asymptomatic participant treated with RGX-111 four years earlier in a phase 1/2 study. An investigation to determine whether the case is drug-related is being conducted, Regenxbio said, adding that causality has not been established.

The FDA's hold on RGX-121 is due to similarities in products, study populations, and shared risk between its clinical studies with RGX-111, the company said.

Regenxbio Chief Executive Curran Simpson said the clinical hold on RGX-121 came as a surprise because RGX-111 and RGX-121 are separate therapies, and RGX-121 has a positive safety profile.

Shares of Regenxbio were down more than 30% in recent premarket activity Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606719765?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-28 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606719765","market":"us","top_or_hot":-1,"title":"Regenxbio Says RGX-111, RGX-121 Placed on Clinical Hold by FDA; Shares Tumble Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Regenxbio (RGNX) said Wednesday that the US Food and Drug Administration has placed a clinical hold on its investigational gene therapies RGX-111 and RGX-121 for potential treatment of Hurler syndrome and Hunter syndrome, respectively.</p><p>The company said the FDA's decision regarding RGX-111 was made after a preliminary analysis of a case of neoplasm in an asymptomatic participant treated with RGX-111 four years earlier in a phase 1/2 study. An investigation to determine whether the case is drug-related is being conducted, Regenxbio said, adding that causality has not been established.</p><p>The FDA's hold on RGX-121 is due to similarities in products, study populations, and shared risk between its clinical studies with RGX-111, the company said.</p><p>Regenxbio Chief Executive Curran Simpson said the clinical hold on RGX-121 came as a surprise because RGX-111 and RGX-121 are separate therapies, and RGX-121 has a positive safety profile.</p><p>Shares of Regenxbio were down more than 30% in recent premarket activity Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regenxbio Says RGX-111, RGX-121 Placed on Clinical Hold by FDA; Shares Tumble Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegenxbio Says RGX-111, RGX-121 Placed on Clinical Hold by FDA; Shares Tumble Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-28 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Regenxbio (RGNX) said Wednesday that the US Food and Drug Administration has placed a clinical hold on its investigational gene therapies RGX-111 and RGX-121 for potential treatment of Hurler syndrome and Hunter syndrome, respectively.</p><p>The company said the FDA's decision regarding RGX-111 was made after a preliminary analysis of a case of neoplasm in an asymptomatic participant treated with RGX-111 four years earlier in a phase 1/2 study. An investigation to determine whether the case is drug-related is being conducted, Regenxbio said, adding that causality has not been established.</p><p>The FDA's hold on RGX-121 is due to similarities in products, study populations, and shared risk between its clinical studies with RGX-111, the company said.</p><p>Regenxbio Chief Executive Curran Simpson said the clinical hold on RGX-121 came as a surprise because RGX-111 and RGX-121 are separate therapies, and RGX-121 has a positive safety profile.</p><p>Shares of Regenxbio were down more than 30% in recent premarket activity Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RGNX","symbol_name":"Regenxbio Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2606719765","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606719765","pubTimestamp":1769605216,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Regenxbio  said Wednesday that the US Food and Drug Administration has placed a clinical hold on its investigational gene therapies RGX-111 and RGX-121 for potential treatment of Hurler syndrome and Hunter syndrome, respectively.The company said the FDA's decision regarding RGX-111 was made after a preliminary analysis of a case of neoplasm in an asymptomatic participant treated with RGX-111 four years earlier in a phase 1/2 study. An investigation to determine whether the case is drug-related is being conducted, Regenxbio said, adding that causality has not been established.The FDA's hold on RGX-121 is due to similarities in products, study populations, and shared risk between its clinical studies with RGX-111, the company said.Regenxbio Chief Executive Curran Simpson said the clinical hold on RGX-121 came as a surprise because RGX-111 and RGX-121 are separate therapies, and RGX-121 has a positive safety profile.Shares of Regenxbio were down more than 30% in recent premarket activity ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RGNX":"Regenxbio Inc","BK4139":"生物科技","BK4505":"高瓴资本持仓","BK4563":"昨日强势股"},"translate_title":"Regenxbio表示RGX-111、RGX-121被FDA搁置临床；盘前股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGNX":1.5},"content_text":"Regenxbio (RGNX) said Wednesday that the US Food and Drug Administration has placed a clinical hold on its investigational gene therapies RGX-111 and RGX-121 for potential treatment of Hurler syndrome and Hunter syndrome, respectively.The company said the FDA's decision regarding RGX-111 was made after a preliminary analysis of a case of neoplasm in an asymptomatic participant treated with RGX-111 four years earlier in a phase 1/2 study. An investigation to determine whether the case is drug-related is being conducted, Regenxbio said, adding that causality has not been established.The FDA's hold on RGX-121 is due to similarities in products, study populations, and shared risk between its clinical studies with RGX-111, the company said.Regenxbio Chief Executive Curran Simpson said the clinical hold on RGX-121 came as a surprise because RGX-111 and RGX-121 are separate therapies, and RGX-121 has a positive safety profile.Shares of Regenxbio were down more than 30% in recent premarket activity Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606719765","isCrawlerRequest":true}